Education
About Us
Working with TipRanks
Follow Us
Evolent Health (EVH)
NYSE:EVH
EVH Stock Chart & Stats
$4.07
<$0.01(0.08%)
At close: 4:00 PM EST
$4.07
<$0.01(0.08%)
Day’s Range― - ―
52-Week Range$3.50 - $12.98
Previous CloseN/A
Volume268.11K
Average Volume (3M)4.76M
Market Cap
$454.22M
Enterprise Value$1.91B
Total Cash (Recent Filing)$116.65M
Total Debt (Recent Filing)$1.08B
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Feb 25, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding111,600,850
10 Day Avg. Volume3,782,794
30 Day Avg. Volume4,761,104
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)1.29
Price to Sales (P/S)0.51
P/FCF Ratio-210.54
Enterprise Value/Market Cap4.20
Enterprise Value/Revenue0.93
Enterprise Value/Gross Profit5.04
Enterprise Value/Ebitda160.45
Forecast
1Y Price Target
$10.14Price Target Upside149.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)0.06
Revenue Forecast (FY)$1.88B
Bulls Say, Bears Say
Bulls Say
Earnings GrowthEVH has recently announced winning approximately $750M in annualized new business, which may generate significant annual earnings over time.
Market PositionEvolent’s unique market position with its focus on value-based specialty care and large growing addressable market supports a robust growth outlook.
New Business And PipelineEvolent has worked to dampen future volatility by narrowing risk corridors while also signing $750M+ of new business, which coupled with a remaining $650M+ pipeline, ongoing margin maturation, and AI initiatives, paves the way for significant longer-range EBITDA growth.
Bears Say
Enrollment ConcernsACA enrollment uncertainty is holding the stock hostage and overshadowing the longer-term outlook.
Leverage And ManagementThere are concerns around EVH's leverage and ability to manage it, which contributes to the stock's decline.
Subsidy UncertaintyThe increasing likelihood that HIX subsidies are not extended jeopardizes 2026 EBITDA growth.
Evolent Health News
EVH FAQ
What was Evolent Health’s price range in the past 12 months?
Evolent Health lowest stock price was $3.50 and its highest was $12.98 in the past 12 months.
What is Evolent Health’s market cap?
Evolent Health’s market cap is $454.22M.
When is Evolent Health’s upcoming earnings report date?
Evolent Health’s upcoming earnings report date is Feb 25, 2026 which is in 69 days.
How were Evolent Health’s earnings last quarter?
Evolent Health released its earnings results on Nov 06, 2025. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.098 by -$0.048.
Is Evolent Health overvalued?
According to Wall Street analysts Evolent Health’s price is currently Undervalued.
Does Evolent Health pay dividends?
Evolent Health does not currently pay dividends.
What is Evolent Health’s EPS estimate?
Evolent Health’s EPS estimate is 0.05.
How many shares outstanding does Evolent Health have?
Evolent Health has 111,600,850 shares outstanding.
What happened to Evolent Health’s price movement after its last earnings report?
Evolent Health reported an EPS of $0.05 in its last earnings report, missing expectations of $0.098. Following the earnings report the stock price went down -17.333%.
Which hedge fund is a major shareholder of Evolent Health?
Currently, no hedge funds are holding shares in EVH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolent Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.14 (149.14% Upside)
$10.14 (149.14% Upside)
Blogger Sentiment
Neutral
EVH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 788.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $38.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 21.7%
Last 30 Days ▲ 21.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.33%
12-Months-Change
Fundamentals
Return on Equity
-13.63%
Trailing 12-Months
Asset Growth
-1.93%
Trailing 12-Months
Company Description
Evolent Health
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
EVH Company Deck
EVH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Evolent's earnings call was largely positive, highlighting financial success and strategic growth through new contracts and partnerships. However, there are challenges related to potential membership reductions in exchange markets and uncertainties in the 2026 financial outlook.View all EVH earnings summariesEVH Stock 12 Month Forecast
Average Price Target
$10.14
▲(149.14% Upside)
Technical Analysis
Ownership Overview
2.32% Insiders
31.32% Mutual Funds
47.33% Other Institutional Investors
3.19% Public Companies and
Individual Investors